On January 8, * ST Changyao announced that the company's shares may be terminated from listing.
Specifically, the company's stock may be forced to delist by trading. Data show that on January 8, the total market value of * ST Changyao was 304.8 million yuan. Stock closing price 0.
companies may be compulsorily delisted in the financial category.".
The announcement shows that the company's stock has been subject to delisting risk warning and other risk warning since April 22, 2025, and has been subject to delisting risk warning since December 29, 2025. In view of the fact that the company has not completed the reorganization before December 31, 2025, the net assets at the end of 2025 are expected to be negative .
According to the listing rules, if the company touches the financial compulsory delisting situation, the company's shares will be terminated from listing.
The company's shares may be forced to delist in violation of major laws.
Previously, in November 2025, * ST Changyao was investigated by the China Securities Regulatory Commission (hereinafter referred to as the "CSRC") on suspicion of false financial data such as periodic reports.
On December 26, the company received the Notice issued by the China Securities Regulatory Commission. Due to the fictitious business of the subsidiary, there are false records in the annual report of * ST Changyao from 2021 to 2023, and the false profit exceeds 1.
According to the public data, * ST Changyao was listed on the Shenzhen Stock Exchange in August 2014. It is a pharmaceutical enterprise focusing on the big health industry. In 2017, the company acquired 100% equity of Hebei Yiheng Science and Technology Co., Ltd. through major asset restructuring. Introducing Solar " the reason for the shutdown, * ST Changyao explained in the announcement: "In view of < a href =" https://www.databm.
浙公网安备33010802003254号